JP7275107B2 - 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 - Google Patents

血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 Download PDF

Info

Publication number
JP7275107B2
JP7275107B2 JP2020508498A JP2020508498A JP7275107B2 JP 7275107 B2 JP7275107 B2 JP 7275107B2 JP 2020508498 A JP2020508498 A JP 2020508498A JP 2020508498 A JP2020508498 A JP 2020508498A JP 7275107 B2 JP7275107 B2 JP 7275107B2
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
methyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020508498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531443A5 (enExample
JP2020531443A (ja
Inventor
ジョバンニ シアンチェッタ，
タオ リウ，
アニル クマール パディアナ，
ジフア スイ，
ジェンウェイ ツァイ，
ダウェイ ツイ，
ジンジン ジ，
Original Assignee
アジオス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジオス ファーマシューティカルズ， インコーポレイテッド filed Critical アジオス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2020531443A publication Critical patent/JP2020531443A/ja
Publication of JP2020531443A5 publication Critical patent/JP2020531443A5/ja
Priority to JP2023005925A priority Critical patent/JP7530453B2/ja
Application granted granted Critical
Publication of JP7275107B2 publication Critical patent/JP7275107B2/ja
Priority to JP2024121066A priority patent/JP2024147805A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020508498A 2017-08-15 2018-08-15 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 Active JP7275107B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023005925A JP7530453B2 (ja) 2017-08-15 2023-01-18 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子
JP2024121066A JP2024147805A (ja) 2017-08-15 2024-07-26 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
CNPCT/CN2017/097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
US62/673,526 2018-05-18
US62/673,533 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023005925A Division JP7530453B2 (ja) 2017-08-15 2023-01-18 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子

Publications (3)

Publication Number Publication Date
JP2020531443A JP2020531443A (ja) 2020-11-05
JP2020531443A5 JP2020531443A5 (enExample) 2021-09-30
JP7275107B2 true JP7275107B2 (ja) 2023-05-17

Family

ID=63524352

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2020508498A Active JP7275107B2 (ja) 2017-08-15 2018-08-15 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子
JP2020508455A Active JP7301040B2 (ja) 2017-08-15 2018-08-15 ピルビン酸キナーゼ調節因子およびその使用
JP2022199462A Pending JP2023027276A (ja) 2017-08-15 2022-12-14 ピルビン酸キナーゼ調節因子およびその使用
JP2023005925A Active JP7530453B2 (ja) 2017-08-15 2023-01-18 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子
JP2024121066A Pending JP2024147805A (ja) 2017-08-15 2024-07-26 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020508455A Active JP7301040B2 (ja) 2017-08-15 2018-08-15 ピルビン酸キナーゼ調節因子およびその使用
JP2022199462A Pending JP2023027276A (ja) 2017-08-15 2022-12-14 ピルビン酸キナーゼ調節因子およびその使用
JP2023005925A Active JP7530453B2 (ja) 2017-08-15 2023-01-18 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子
JP2024121066A Pending JP2024147805A (ja) 2017-08-15 2024-07-26 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子

Country Status (34)

Country Link
US (8) US11590132B2 (enExample)
EP (4) EP3668512B1 (enExample)
JP (5) JP7275107B2 (enExample)
KR (3) KR102764124B1 (enExample)
CN (3) CN111032045B (enExample)
AU (4) AU2018316588B2 (enExample)
BR (2) BR112020003254A2 (enExample)
CA (1) CA3072455A1 (enExample)
CL (1) CL2020000375A1 (enExample)
CO (2) CO2020002961A2 (enExample)
CR (1) CR20200123A (enExample)
CY (1) CY1124953T1 (enExample)
DK (2) DK3668512T3 (enExample)
EC (1) ECSP20018487A (enExample)
ES (3) ES2966825T3 (enExample)
FI (1) FI3668512T3 (enExample)
HR (2) HRP20220039T1 (enExample)
HU (2) HUE057178T2 (enExample)
IL (3) IL272599B (enExample)
LT (2) LT3668512T (enExample)
MD (1) MD3668513T2 (enExample)
MX (2) MX2020001832A (enExample)
MY (1) MY204421A (enExample)
PE (1) PE20200724A1 (enExample)
PH (1) PH12020500343B1 (enExample)
PL (2) PL3668512T3 (enExample)
PT (2) PT3668512T (enExample)
RS (2) RS62871B1 (enExample)
SG (2) SG11202001353PA (enExample)
SI (2) SI3668513T1 (enExample)
SM (2) SMT202200023T1 (enExample)
TW (3) TWI823580B (enExample)
UA (1) UA126292C2 (enExample)
WO (3) WO2019035864A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
MX2020001832A (es) * 2017-08-15 2020-07-22 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
WO2019079541A1 (en) 2017-10-20 2019-04-25 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
BR112021015996A2 (pt) * 2019-02-13 2021-11-09 Agios Pharmaceuticals Inc Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes
TWI856118B (zh) * 2019-06-26 2024-09-21 日商日產化學股份有限公司 電荷輸送性塗料
EP4031132A4 (en) 2019-09-19 2023-09-13 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2022020424A1 (en) * 2020-07-21 2022-01-27 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
TW202245758A (zh) 2021-02-08 2022-12-01 美商全球血液治療公司 作為丙酮酸激酶活化劑之吡咯啶-吡唑
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
US20240409542A1 (en) * 2021-09-30 2024-12-12 Sitryx Therapeutics Limited Novel compounds
EP4433057A1 (en) * 2021-11-16 2024-09-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
CN121175238A (zh) 2023-03-28 2025-12-19 本田技研工业株式会社 信息提供方法、信息提供程序、存储介质及信息处理装置
AU2024271856A1 (en) 2023-05-15 2025-11-27 Agios Pharmaceuticals, Inc. Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2025010390A1 (en) * 2023-07-05 2025-01-09 Agios Pharmaceuticals, Inc. Synthesis of pyruvate kinase activators
WO2025207563A1 (en) 2024-03-27 2025-10-02 Agios Pharmaceuticals, Inc. Use of a pk activator in the treatment of sickle cell disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505247A (ja) 2008-10-09 2012-03-01 アメリカ合衆国 ヒトピルビン酸キナーゼ活性化剤
WO2012151450A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
JP2016512203A (ja) 2013-03-15 2016-04-25 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
IL147757A0 (en) 1999-07-30 2002-08-14 Abbott Gmbh & Co Kg 2-pyrazolin-5-ones
MXPA02002319A (es) 1999-09-04 2002-07-30 Astrazeneca Ab Derivados 2-hidroxi-2-metil-3,3,3-trifluoropropanamida con n-fenilo susbtituido que elevan la actividad de la deshidrogenasa de piruvato.
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP2011529066A (ja) * 2008-07-23 2011-12-01 バーテックス ファーマシューティカルズ インコーポレイテッド 三環式ピラゾロピリジンキナーゼ阻害剤
EP2334673A1 (en) * 2008-08-29 2011-06-22 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
CN102448951B (zh) * 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
PT2448582T (pt) 2009-06-29 2017-07-10 Agios Pharmaceuticals Inc Compostos e composições terapêuticas
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
EA023796B1 (ru) 2010-12-06 2016-07-29 Глэксо Груп Лимитед ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CN108451955B (zh) 2011-05-03 2022-02-01 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
WO2012151452A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use in therapy
WO2012151448A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
WO2013012915A1 (en) * 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
US9458132B2 (en) 2012-11-08 2016-10-04 Agios Pharmaceuticals, Inc Therapeutic compounds and compositions and their use as PKM2 modulators
JP2016506943A (ja) * 2013-01-30 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
LT3661925T (lt) 2017-07-07 2022-03-10 Inflazome Limited Naujieji sulfonamido karboksamido junginiai
CA3071150A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
SG11202001182QA (en) 2017-08-15 2020-03-30 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
MX2020001832A (es) 2017-08-15 2020-07-22 Agios Pharmaceuticals Inc Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
BR112021015996A2 (pt) * 2019-02-13 2021-11-09 Agios Pharmaceuticals Inc Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505247A (ja) 2008-10-09 2012-03-01 アメリカ合衆国 ヒトピルビン酸キナーゼ活性化剤
WO2012151450A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
JP2016512203A (ja) 2013-03-15 2016-04-25 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物

Also Published As

Publication number Publication date
DK3668513T3 (da) 2022-01-10
CA3072455A1 (en) 2019-02-21
PL3668512T3 (pl) 2023-06-19
US20210130371A1 (en) 2021-05-06
HUE061910T2 (hu) 2023-08-28
PT3668512T (pt) 2023-05-22
MX2020001832A (es) 2020-07-22
EP3668881A1 (en) 2020-06-24
CN111032046A (zh) 2020-04-17
US11872225B2 (en) 2024-01-16
TW201919631A (zh) 2019-06-01
CN117186119A (zh) 2023-12-08
SG11202001353PA (en) 2020-03-30
AU2018316587A1 (en) 2020-02-20
IL272599A (en) 2020-03-31
CN111032045A (zh) 2020-04-17
TW202323258A (zh) 2023-06-16
JP2023027276A (ja) 2023-03-01
CN111032046B (zh) 2023-09-26
BR112020003254A2 (pt) 2020-10-27
AU2018316587B2 (en) 2023-05-11
LT3668513T (lt) 2022-03-25
JP2024147805A (ja) 2024-10-16
KR20230127364A (ko) 2023-08-31
ES2905100T3 (es) 2022-04-07
JP2020531432A (ja) 2020-11-05
IL272599B (en) 2022-08-01
HUE057178T2 (hu) 2022-04-28
US20200206225A1 (en) 2020-07-02
IL292530B2 (en) 2023-06-01
DK3668512T3 (da) 2023-05-22
HRP20220039T1 (hr) 2022-04-15
IL272597B (en) 2022-06-01
SMT202300146T1 (it) 2023-07-20
AU2018316588B2 (en) 2023-02-02
AU2018316588A1 (en) 2020-02-20
AU2023202772A1 (en) 2023-05-18
CN111032045B (zh) 2023-08-15
US11590132B2 (en) 2023-02-28
CO2020002961A2 (es) 2020-04-13
RU2020110573A (ru) 2021-09-16
BR112020003262A2 (pt) 2020-09-01
JP7301040B2 (ja) 2023-06-30
KR102642408B1 (ko) 2024-02-28
US20230226055A1 (en) 2023-07-20
WO2019035863A8 (en) 2019-03-28
US20250144093A1 (en) 2025-05-08
RS64221B1 (sr) 2023-06-30
US20220395503A1 (en) 2022-12-15
KR102764124B1 (ko) 2025-02-05
WO2019035863A1 (en) 2019-02-21
EP3668512A1 (en) 2020-06-24
PH12020500343A1 (en) 2021-02-08
CR20200123A (es) 2020-06-29
US11364240B2 (en) 2022-06-21
MY204421A (en) 2024-08-28
US20220233541A1 (en) 2022-07-28
CO2020002959A2 (es) 2020-04-13
PH12020500343B1 (en) 2024-02-21
AU2023202772B2 (en) 2024-05-16
PE20200724A1 (es) 2020-07-21
MD3668513T2 (ro) 2022-04-30
KR20200054200A (ko) 2020-05-19
LT3668512T (lt) 2023-06-12
HRP20230452T1 (hr) 2023-07-21
CY1124953T1 (el) 2023-01-05
JP2023052478A (ja) 2023-04-11
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
US11957680B2 (en) 2024-04-16
EP3668513B1 (en) 2021-11-10
ECSP20018487A (es) 2020-05-29
AU2024205818A1 (en) 2024-09-05
TWI790271B (zh) 2023-01-21
US20200207785A1 (en) 2020-07-02
CA3071993A1 (en) 2019-02-21
ES2966825T3 (es) 2024-04-24
CL2020000375A1 (es) 2020-12-11
SI3668513T1 (sl) 2022-04-29
WO2019035864A8 (en) 2019-03-28
IL272597A (en) 2020-03-31
RS62871B1 (sr) 2022-02-28
JP2020531443A (ja) 2020-11-05
TW201920203A (zh) 2019-06-01
TWI796353B (zh) 2023-03-21
SMT202200023T1 (it) 2022-03-21
SG11202001262QA (en) 2020-03-30
EP3668513A1 (en) 2020-06-24
KR102717594B1 (ko) 2024-10-14
JP7530453B2 (ja) 2024-08-07
KR20200054199A (ko) 2020-05-19
US12133853B2 (en) 2024-11-05
EP4026838A1 (en) 2022-07-13
FI3668512T3 (fi) 2023-05-12
EP3668512B1 (en) 2023-02-15
WO2019035865A8 (en) 2019-03-28
US11464775B2 (en) 2022-10-11
WO2019035864A1 (en) 2019-02-21
UA126292C2 (uk) 2022-09-14
US20210077490A1 (en) 2021-03-18
MX2020001833A (es) 2020-07-22
WO2019035865A1 (en) 2019-02-21
US11040036B2 (en) 2021-06-22
SI3668512T1 (sl) 2023-06-30
RU2020110573A3 (enExample) 2021-12-24
ES2944545T3 (es) 2023-06-22
EP3668881B1 (en) 2023-10-04
IL292530A (en) 2022-06-01
PL3668513T3 (pl) 2022-03-21

Similar Documents

Publication Publication Date Title
JP7275107B2 (ja) 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子
HK40077435A (en) Pyruvate kinase activators for use in treating blood disorders
CA3071993C (en) Thiazolo(5',4':4,5)pyrrolo(2,3-d)pyridazine-5-one derivatives and pharmaceutical compositions thereof useful as pyruvate kinase activators for use in treating blood disorders
HK40030323B (en) Pyruvate kinase activators for use in treating blood disorders
EA042084B1 (ru) Активаторы пируваткиназы для применения в лечении нарушений со стороны крови
EA046698B1 (ru) Активаторы пируваткиназы для применения в лечении нарушений со стороны крови

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210813

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230502

R150 Certificate of patent or registration of utility model

Ref document number: 7275107

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150